Ken Griffin Eloxx Pharmaceuticals, Inc. Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.15 - $7.2 $7,970 - $382,593	-53,138 Reduced 47.55%	58,622 $10,000
Q2 2022 Aug 15, 2022	BUY	$0.24 - $0.58 $26,822 - $64,820	111,760 New	111,760 $30,000
Q1 2022 May 16, 2022	SELL	$0.4 - $0.72 $8,940 - $16,092	-22,350 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$0.62 - $1.61 $50,801 - $131,920	-81,938 Reduced 78.57%	22,350 $15,000
Q3 2021 Nov 15, 2021	BUY	$1.22 - $2.0 $3,206 - $5,256	2,628 Added 2.59%	104,288 $170,000
Q2 2021 Aug 16, 2021	BUY	$1.35 - $3.36 $137,241 - $341,577	101,660 New	101,660 $202,000
Q2 2020 Aug 14, 2020	SELL	$1.56 - $3.65 $24,407 - $57,107	-15,646 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$1.96 - $7.96 $30,666 - $124,542	15,646 New	15,646 $31,000

Ticker ELOX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 86,656,200
Description
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis p...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.